What Бильтрицид Treats: Main Uses and Benefits

The core therapeutic function of Бильтрицид is the comprehensive management of parasitic infections caused by flatworms. The medication is commonly used to help with conditions characterized by periods of heightened symptoms related to parasitic infestation.

The primary use is the management of infections caused by flukes (trematodes), including schistosomiasis (blood flukes) and key liver flukes (clonorchiasis, opisthorchiasis). It also assists with managing various tapeworms (cestodes), including intestinal species and the more complex larval-stage tapeworm infections like cysticercosis. The central benefit to the patient may involve the removal of the parasites, which supports the reduction of the overall parasitic burden.

This treatment is applied in clinical settings that involve acute or unstable symptom patterns affecting the urinary tract, bowels, and hepatobiliary system. The treatment is relevant for addressing the underlying parasitic presence, which supports easing the overall symptom load during symptomatic periods. It is also relevant in large-scale public health strategies for preventive chemotherapy.

The medication may assist in reducing the likelihood of chronic organ functional stress and contributes to improved comfort, helping patients cope more steadily with symptomatic periods.

---

Quick Fact: Relief for Parasitic Symptoms

Property	Description
Primary Use	Management of parasitic infections caused by flatworms (trematodes and cestodes).
Target Conditions	Schistosomiasis, Clonorchiasis, Opisthorchiasis, and intestinal/larval tapeworm infections.
Core Benefit	Supports the reduction of the parasitic burden to ease the overall symptom load.
Usage Context	Individual patient treatment and public health programs (Mass Drug Administration).

Regulatory References

1. DailyMed, NIH Praziquantel Label

Official Population Eligibility for Бильтрицид

The eligibility for Бильтрицид (Praziquantel) is defined by official regulatory bodies based on age, pre-existing conditions, and physiological status. Use is generally established for patients aged 1 year and older for the treatment of susceptible infections, but specific contraindications and limitations apply.

Classification	Rule (Official Regulatory Statement)
Absolute Contraindication	Patients with known hypersensitivity to Praziquantel or excipients.
Absolute Contraindication	Patients with ocular cysticercosis (due to the risk of irreversible lesions).
Absolute Contraindication	Co-administration with strong Cytochrome P450 (CYP450) inducers (e.g., rifampin).
Age Restriction	Safety has not been established in pediatric patients younger than 1 year of age.
Conditional Use	Caution is required for patients with moderate to severe liver impairment (Child-Pugh Class B and C).
Conditional Use	Should generally not be administered to individuals with a history of epilepsy or other signs of potential Central Nervous System (CNS) involvement.
Pregnancy/Lactation	Classified as Pregnancy Category B (legacy FDA); nursing must be suspended on the day of treatment and for the subsequent 72 hours.

Interactions with other medicines and products

Official Interaction Profile

The interaction profile of Бильтрицид (Praziquantel) is defined by its reliance on the Cytochrome P450 (CYP) enzyme system, primarily CYP3A4, for metabolism. This leads to pharmacokinetic interactions documented in regulatory labeling that alter the medicine's concentration in the body.

Classification	Description of Official Restriction
Contraindicated Combinations	Strong CYP450 inducers, such as Rifampin and St John’s Wort (Hypericum perforatum), are officially contraindicated due to the severe decrease in Praziquantel plasma levels, potentially resulting in therapeutically ineffective concentrations.
Mandatory Timing Rule	If treatment with Бильтрицид is required, Rifampin must be discontinued four weeks before the administration of Praziquantel.

Documented Exposure Modification

Co-administration with other substances can lead to changes in Praziquantel exposure:

• Decreased Exposure: Moderate CYP inducers, including certain antiepileptic medicines like Phenytoin, Phenobarbital, and Carbamazepine, as well as Dexamethasone, increase CYP3A4 activity and reduce Praziquantel plasma concentrations.
• Increased Exposure: CYP inhibitors, such as Cimetidine, Ketoconazole, Itraconazole, and Erythromycin, may decrease enzyme activity and consequently increase Praziquantel plasma concentrations.
• Food and Supplements: Grapefruit Juice has been documented to increase the maximum plasma concentration (Cmax) and the overall exposure (AUC) of Praziquantel.

Population-Specific Interaction Notes

Regulatory documents note that in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C), reduced liver metabolism of Praziquantel leads to considerably higher and longer lasting plasma concentrations of the unmetabolized drug, which can amplify the effect of co-administered agents that inhibit CYP activity.

Molecular Disruption via Calcium Influx

The core mechanism of Praziquantel involves the rapid activation of specific ion channels (like the Schistosome TRPMPZQ) within the parasite's outer protective layer, the tegument. This action leads to a massive, uncontrolled influx of calcium ions ( Ca^2+) from the external environment into the worm's cells, which results in the rapid destabilization of the parasite's internal cellular environment and calcium-dependent physiological processes.

Paralysis and Structural Integrity Failure

The sudden surge of intracellular Ca^2+ triggers an immediate and irreversible spastic paralysis and tetanic contraction of the parasite's musculature, causing it to detach from the host tissue. Concurrently, the calcium overload causes severe structural damage and vacuolization of the tegument. This mechanism involves the unmasking of parasite antigens, engaging the host's immune response against the compromised organism.

Mechanism Constraints

The mechanism is active against adult worms but exhibits stage-dependent limitations, showing reduced effectiveness against juvenile (immature) parasite forms. This constraint is rooted in the biological differences between life stages, which do not fully trigger the same degree of Ca^2+ influx or subsequent structural and neuromuscular consequences.

The administration of Praziquantel is structured as a single-day course of therapy for approved infections, utilizing the 600 mg film-coated tablets for the oral route. The regimen is strictly bodyweight-based, and the 600 mg tablets are scored to permit division into 150 mg segments, allowing for necessary dose adjustments.

Dosing and Frequency

The total daily dose is administered in three separate doses taken at intervals of 4 to 6 hours on the treatment day. The dosing for adults and children aged 1 year and older depends on the specific infection:

Indication	Dose per Administration (TID)
Schistosomiasis	20 mg/kg bodyweight
Clonorchiasis/Opisthorchiasis	25 mg/kg bodyweight

Administration Conditions and Handling

All doses must be taken with water during meals to align with recommended administration conditions. The tablets or segments must be swallowed whole without chewing or holding them in the mouth, a constraint imposed by the bitter taste that can cause gagging. If a dose is missed, it should be taken as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose must be skipped.

For pediatric patients under 6 years of age, the tablets may be crushed or disintegrated and mixed with liquid or semi-solid food to facilitate administration. The prepared mixture must be used within 1 hour of mixing.

Research Evidence / Overview of Studies for Бильтрицид

Evidence for use in Schistosomiasis Studies

Research has extensively explored the use of Бильтрицид in people with schistosomiasis, which is caused by blood flukes. A large volume of evidence exists, primarily from Randomized Controlled Trials (RCTs) and Systematic Reviews, which compare different treatment schedules and monitored outcomes in highly affected areas. Studies monitored key outcomes such as the Parasitological Cure Rate (whether parasite eggs were absent after treatment) and the Egg Reduction Rate (ERR) over short follow-up intervals, typically one to two months.

Studies consistently reported measurements of cure rates and egg reduction rates in the observed populations. Data gathered from large-scale public health programs also provides insight into these parasitological outcomes across wider communities. Furthermore, researchers also tracked morbidity markers, such as indicators of organ stress or fibrosis, over longer observation periods.

Evidence for use in Foodborne Trematode Infections

Бильтрицид was evaluated in studies focusing on infections caused by liver flukes, such as Clonorchiasis and Opisthorchiasis. Research examined the use of the medicine in populations from endemic regions who have these specific foodborne parasitic conditions. The studies monitored the Parasitological Cure Rate and collected patient-reported outcomes describing perceived discomfort or clinical improvement over relatively short follow-up periods, often 30 to 60 days.

Studies reported measurements of cure rates for both Clonorchis sinensis and Opisthorchis viverrini infections in the populations examined. This evidence contributes to the broader evidence landscape for conditions involving periods of heightened symptoms related to these flukes. However, the evidence base is considered more limited compared to that for schistosomiasis, and the overall quality of available evidence varies across studies.

What is Still Uncertain About Бильтрицид

A number of research gaps and limitations exist in the current body of evidence. Evidence quality varies across studies, particularly for some of the less common indications like larval tapeworm infections. Long-term effects are not fully established for all outcomes, particularly the durability of the effect after treatment is completed and the length of observation periods. Research continues to explore the time intervals examined for retreatment in public health programs, and studies are ongoing to monitor the clinical significance of reports documenting reduced parasite susceptibility in certain geographic areas.

Key Studies & References

1. Clinical Efficacy and Tolerability of Praziquantel for Intestinal and Urinary Schistosomiasis—A Meta-analysis of Comparative and Non-comparative Clinical Trials
2. Albendazole versus Praziquantel in the Treatment of Neurocysticercosis: A Meta-analysis of Comparative Trials

Common questions about Бильтрицид (FAQ)

Q: What symptoms indicate a serious allergic reaction to Бильтрицид?

Official product information states that signs of a serious allergic reaction may include a skin rash, hives, and swelling that affects the face, lips, tongue, or throat. These reactions are rare, and immediate medical attention is described as necessary if these symptoms occur.

---

Q: Why does the official information contain warnings about driving or operating machinery?

The official product information contains warnings against driving or operating heavy machinery because the medication can cause side effects like dizziness and drowsiness (somnolence). These central nervous system effects may impair coordination, reaction time, and judgment.

---

Q: What are the major drug categories that interact with Бильтрицид?

Regulatory documents indicate that the medicine's effectiveness can be altered by drugs that affect the Cytochrome P450 (CYP) enzyme system in the liver. This includes strong or moderate CYP inducers, such as certain antiepileptic medicines, and CYP inhibitors, such as certain antifungal agents.

---

Q: Can people with different types of cysticercosis safely take this drug?

The use of the medicine is contraindicated (forbidden) in patients diagnosed with ocular cysticercosis due to the risk of irreversible lesions in the eye. For patients with cerebral cysticercosis, official guidance states that administration is required under hospital supervision.

---

Q: Is it necessary to take Бильтрицид with food, and if so, why?

The medicine must be taken with water during meals. This is because the tablets have a bitter taste, and official instructions require that the tablets or segments be swallowed whole without chewing. Holding them in the mouth can cause gagging or vomiting.

---

Q: How long after the last dose is it safe to drive again?

Due to the potential for dizziness and impaired coordination, official safety information indicates the restriction of driving and machinery operation is in place for the day of treatment and the following 24 hours after the last dose.

---

Q: Is loss of appetite a possible side effect of Бильтрицид?

Loss of appetite (anorexia) has been reported as an adverse event. This information comes from reports gathered during the drug's post-marketing experience, as documented in regulatory sources.

---

Q: Does the leaflet mention muscle aches or joint pain after treatment?

Yes, reports from the post-marketing period have included occurrences of muscle pain (myalgia) and joint pain or stiffness as undesirable effects. This information is noted in regulatory documentation on the drug’s safety profile.

---

Q: Is it safe to consume alcohol during the treatment period?

Official patient information notes that consuming alcohol during the treatment period can increase the risk of certain central nervous system side effects, such as feeling dizzy or lightheaded.

---

Q: Can over-the-counter medicines affect the safety or effectiveness of Бильтрицид?

The official product information requires the disclosure of all prescription and nonprescription (over-the-counter) medicines or supplements to the healthcare provider. This is necessary because some non-prescription products may interact with Praziquantel.

---

Q: What kind of kidney issues might require caution when using this medication?

Regulatory documents state that approximately 80% of the medicine is eliminated from the body by the kidneys after being metabolized. While routine dose adjustment is not usually necessary for renal impairment, the elimination of the medicine may be slower in patients with reduced kidney function.

---

Q: Are there special considerations or warnings for elderly patients?

Clinical experience reported in regulatory documents has not generally identified differences in response between elderly and younger patients. However, special consideration is given because elderly patients may have naturally decreased renal function, which could increase the risk of toxic reactions.

---

Q: How quickly is the drug eliminated from the body?

Official clinical pharmacology data indicates that the medicine is eliminated relatively quickly. The serum half-life of the unchanged active ingredient in the bloodstream is typically short, ranging from 0.8 to 1.5 hours in adults with normal kidney and liver function.

---

Q: Why is it important to complete the entire course of treatment even if I feel better quickly?

Official patient leaflets note that the required course of therapy should be completed as prescribed by a physician, even if symptoms show early improvement.

---

Q: Are there documented cases of overdose with this medicine?

The official product information describes the management of a suspected overdose as involving supportive care and the potential use of activated charcoal to reduce absorption.

---

Q: Why do some people experience bloody diarrhea as a less common side effect?

Bloody diarrhea is listed in regulatory documentation as a reported undesirable effect following the drug's use. The specific physiological reason why this occurs is not detailed in the available patient-facing regulatory information.

Storage and Disposal Conditions for Biltricide (Praziquantel)

Biltricide tablets must be stored at Controlled Room Temperature, which is defined by regulatory standards as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and protected from light. Storage temperatures must not exceed 30 C.

Stability and Child Safety

Official labeling mandates that Biltricide must be stored out of the sight and reach of children. For some packaging, a stability rule requires the product to be discarded 28 days after initial opening of the container.

Disposal Requirements

Unused or expired Biltricide must be disposed of in accordance with local requirements for pharmaceutical waste. If no local drug take-back program is available, the unused medicine should be disposed of in the household trash after mixing with an undesirable substance, following federal guidelines.